GlobeNewsWire
14 Jul 2026, 12:34 UTC · 11w ago
Verdict
Headline takes no side. We score ICU +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 89% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Real-world data from the QUELIMMUNE SAVE Registry shows a 76% survival rate at 60 days, validating a 50% reduction in mortality compared to historical data.
More positive than 93% of claims this week
SeaStar Medical is launching a targeted educational webinar on August 11, 2026, specifically to promote the use of QUELIMMUNE therapy to pediatric clinicians.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 67% of claims this week
The QUELIMMUNE therapy was approved in February 2024 under a Humanitarian Device Exemption (HDE) for pediatric patients with AKI and sepsis.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company is promoting its FDA-approved QUELIMMUNE therapy and reporting positive clinical data showing a significant reduction in patient mortality.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
39m ago
−30.9%
Price is moving against the score
$3.31 vs $4.79 close before publication (Jul 13) · not market-adjusted
ICU chart →
